Dual-Target CSPG4/GD2 CAR-NK Cells for Advanced Melanoma
A phase 1/2 trial of Fludarabine, Cyclophosphamide in melanoma and uveal melanoma, run by Beijing Biotech, now recruiting.
Overview
Dual-Target CSPG4/GD2 CAR-NK Cells for Advanced Melanoma is a phase 1/2 interventional study registered as NCT07627698 by Beijing Biotech, with 36 participants planned, started 2026-03-02 and due to reach its primary completion in 2027-06-14. Interventions recorded: EB-DTKN-401 allogeneic dual-target CSPG4/GD2 CAR-NK cells, Fludarabine, Cyclophosphamide. Conditions listed: Unresectable Melanoma, Metastatic Cutaneous Melanoma, Metastatic Uveal Melanoma. No results are recorded here; the registry entry is the source.
Similar pages
not linked directly; found by shared links- TrialBiomarker-Guided Dual-Target CAR-T Cells for Advanced Solid Tumors
Shares Fludarabine, Cyclophosphamide.
- TrialDual-Targeting CAR-NK Cells Targeting Mesothelin (MSLN) and MUC1 in Advanced Pancreatic Ductal Adenocarcinoma
Shares Fludarabine, Cyclophosphamide.
- TrialDual-Target CAR-NK Cells Targeting Mesothelin (MSLN) and MUC1 in Advanced Pancreatic Ductal Adenocarcinoma
Shares Fludarabine, Cyclophosphamide.
- TrialDual-Target CAR-NK Cells in Recurrent or Refractory Epithelial Ovarian Cancer
Shares Fludarabine, Cyclophosphamide.
- TrialDual-target CLDN18.2/HER2 CAR-NK Cells for Advanced Gastric/GEJ Cancer
Shares Fludarabine, Cyclophosphamide.
- TrialDual-Target GPC3/B7-H3 CAR-NK Cells for Advanced HCC
Shares Fludarabine, Cyclophosphamide.
- TrialDual-Target GD2/B7-H3 CAR-NK Cells for Pediatric Relapsed or Refractory Neuroblastoma
Shares Fludarabine, Cyclophosphamide.
- TrialDual-Target HER2/CEA CAR-NK Cells in Advanced Biliary Tract Cancer
Shares Fludarabine, Cyclophosphamide.